Linagliptin/Pioglitazone Hydrochloride

利格列汀/盐酸吡格列酮

Report date: 2026/03/23 20:03:44

Base Information

Drug NameLinagliptin/Pioglitazone Hydrochloride

Drug Alias Name盐酸吡格列酮/利格列汀Pioglitazone Hydrochloride/LinagliptinLinagliptin and Pioglitazone HydrochloridePioglitazone Hydrochloride and LinagliptinPioglitazone/linagliptin +[6]

ClassificationSmall molecules

Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsDipeptidyl peptidase IV inhibitors

TargetsDipeptidyl peptidase IVPeroxisome proliferator-activated receptor γ

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Linagliptin Pioglitazone Hydrochloride

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A